{"filings":[{"id":92798,"accession_number":"0001140361-26-020036","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BMY shareholders elect all 11 directors, pass say-on-pay, stock plan, auditor; independent chair proposal fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected with >1.46B votes for each.","Say-on-pay approved: 1.46B for, 72.5M against, 6.9M abstain.","2026 stock award and incentive plan approved: 1.47B for, 63.9M against.","Ratification of Deloitte & Touche as 2026 auditor: 1.71B for, 63.7M against.","Shareholder proposal for independent board chair defeated: 422M for, 1.11B against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92797,"accession_number":"0000014272-26-000008","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q1 revenue $11.5B (+3%); reaffirms 2026 guidance trending upper end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $11.5B, up 3% YoY (1% ex-FX); Growth Portfolio revenue $6.2B (+12% / +9% ex-FX).","GAAP EPS $1.31; non-GAAP EPS $1.58; both include $(0.03) net impact from Acquired IPRD and licensing.","FY 2026 guidance reaffirmed: revenue ~$46.0-47.5B, non-GAAP EPS $6.05-6.35, trending toward upper end.","CEO highlights strong execution and pipeline milestones ahead for patients and shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":11489000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103931,"accession_number":"0000014272-26-000002","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q4 rev $12.5B (+1%), non-GAAP EPS $1.26; dividend raised to $0.63/share; FY2026 guidance rev $46-47.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $12.5B (+1% YoY); Growth Portfolio rev $7.4B (+16%). Full-year rev $48.2B.","GAAP EPS Q4 $0.53, FY $3.46; Non-GAAP EPS Q4 $1.26, FY $6.15.","2026 guidance: revenue ~$46-47.5B, non-GAAP EPS $6.05-6.35.","Quarterly dividend raised to $0.63/share, 17th consecutive annual increase.","Acquired IPRD charges and licensing income net impact of $(0.60) on Q4 EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":3.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":48194000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103930,"accession_number":"0001140361-26-000929","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bristol Myers Squibb posts investor presentation at J.P. Morgan Healthcare; no specific updates in filed excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Christopher Boerner, Board Chair & CEO, presented at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.","Presentation titled 'Built for Growth' posted on company website at bms.com/investors/events-and-presentations.html.","No specific financial metrics, guidance changes, or pipeline updates are included in the filed portion of the presentation.","Filing under Regulation FD; information furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120204,"accession_number":"0001140361-25-042607","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BMY completes early settlement of ~$7.5B tender offers for 15 note series","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended Pool 1 max purchase price to ~$3.99B; Pool 2 max to ~$3.51B.","All validly tendered Pool 1 notes and Pool 2 notes (priority 1-4) accepted at 100%; 2033 notes prorated at ~50.84%.","Early Settlement Date set for November 20, 2025; no further tenders will be accepted.","Total consideration per $1,000 principal ranged from $985.66 to $1,129.13 depending on series.","Accepted notes will be cancelled and retired; interest ceases on settlement date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120203,"accession_number":"0001140361-25-041380","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BMY subsidiary issues €5B notes (2.973%-4.581%) to fund tender offer and general purposes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €5B across five tranches: €750M (2030, 2.973%), €1.15B (2033, 3.363%), €1.15B (2038, 3.857%), €750M (2045, 4.289%), €1.2B (2055, 4.581%).","Proceeds plus ~$3B cash on hand will fund a tender offer for existing BMY notes and pay fees.","Notes are fully and unconditionally guaranteed by BMY on a senior unsecured basis.","Interest payable annually on Nov 10 beginning Nov 10, 2026; optional redemption at make-whole spreads of +10 to +20 bps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120202,"accession_number":"0001140361-25-040066","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb launches $7B cash tender offer for 15 series of outstanding notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offers up to $4B for Pool 1 notes (2026-2029 maturities) and $3B for Pool 2 notes (2031-2097).","Early tender deadline Nov 17, 2025; expiration Dec 3, 2025; early tender premium $50 per $1,000 principal.","Financing from new debt offering by subsidiary plus ~$3B cash on hand; accepted notes will be cancelled.","Dealer managers: Citigroup, Deutsche Bank, Goldman Sachs, Morgan Stanley."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120201,"accession_number":"0000014272-25-000147","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q3 revenue $12.2B (+3% YoY), GAAP EPS $1.08, raises FY revenue guidance to ~$47.5-48B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $12,222M (+3% YoY; +2% ex-FX); Growth Portfolio $6.9B (+18% ex-FX).","GAAP EPS $1.08 (up 81% YoY); non-GAAP EPS $1.63 (down 9% YoY); both include $(0.20) net impact from Acquired IPRD and licensing.","FY 2025 revenue guidance raised to ~$47.5B-$48.0B; non-GAAP EPS expected $6.40-$6.60 (includes $(0.80) net Acquired IPRD impact).","Q3 2024 comparatives: revenue $11,892M, GAAP EPS $0.60, non-GAAP EPS $1.80.","CEO cites Growth Portfolio momentum, pipeline advancements, and strategic business development."],"consensus_eps_estimate":null,"consensus_eps_actual":2.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":35692000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136778,"accession_number":"0000014272-25-000129","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BMY Q2 revenue $12.3B, GAAP EPS $0.64, non-GAAP EPS $1.46; raises revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.3B, +1% YoY; Growth Portfolio $6.6B, +18% YoY (+17% ex-FX).","GAAP EPS $0.64 vs $0.83 YoY; non-GAAP EPS $1.46 vs $2.07 YoY, both hit by $(0.57) BioNTech IPRD charge.","2025 revenue guidance raised to ~$46.5B–$47.5B; non-GAAP EPS guidance updated to $6.35–$6.65.","BioNTech strategic partnership resulted in a $0.57 per share Acquired IPRD charge in Q2.","CEO cites strong Growth Portfolio execution, cost optimization, and pipeline partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":23470000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136777,"accession_number":"0001140361-25-027350","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bristol Myers Squibb appoints Cristian Massacesi as CMO; Samit Hirawat departs by Nov 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cristian Massacesi, M.D., named EVP, Chief Medical Officer and Head of Development, effective August 1, 2025.","Samit Hirawat, M.D., steps down as CMO and Head of Development on August 1; will remain advisor through November 1, 2025.","Massacesi will oversee early- and late-stage development across all therapeutic areas and serve on Executive Leadership Team.","Hirawat leaves after six years; company cites his role in advancing pipeline across oncology, hematology, immunology, cardiovascular, neuroscience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154000,"accession_number":"0001140361-25-017742","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BMY shareholders elect all 11 directors, approve compensation, at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected; votes 'for' ranged from 1.49B to 1.53B.","Advisory vote on executive compensation approved: 1.44B for, 92M against.","Ratification of Deloitte as auditor approved: 1.72B for, 59M against.","Shareholder proposal on corporate financial sustainability defeated: 17.6M for, 1.51B against.","Shareholder proposal to cease DEI efforts defeated: 26.5M for, 1.50B against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153999,"accession_number":"0000014272-25-000089","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb Q1 revenue $11.2B (-6% YoY), GAAP EPS $1.20, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $11.2B, down 6% (4% ex-FX) from $11.865B in Q1 2024.","Growth Portfolio revenues $5.6B, up 16% (18% ex-FX) driven by new launches.","GAAP EPS $1.20; non-GAAP EPS $1.80, compared to prior-year losses of $5.89 and $4.40 respectively.","FY 2025 revenue guidance raised to ~$45.8B-$46.8B, non-GAAP EPS raised to $6.70-$7.00.","CEO cites strong execution and pipeline progress; multi-year transformation plans on track."],"consensus_eps_estimate":null,"consensus_eps_actual":1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":11201000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172640,"accession_number":"0001140361-25-005012","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bristol-Myers General Counsel Sandra Leung to retire in 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra Leung notified company of her retirement from EVP, General Counsel role, effective in 2025.","She will remain for a transition period until successor is appointed.","Retirement benefits will be provided under existing compensation plans.","Successor not yet named; transition expected before year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172639,"accession_number":"0000014272-25-000037","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BMY Q4 rev +8% to $12.3B, GAAP EPS $0.04; expands cost-savings by $2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenues $12.3B (+8% YoY, +9% ex-FX); GAAP EPS $0.04, Non-GAAP EPS $1.67.","Full-year 2024 revenues $48.3B (+7% YoY); GAAP loss per share $(4.41), Non-GAAP EPS $1.15.","Growth Portfolio revenues $22.6B for FY24 (+17%, +19% ex-FX); Q4 $6.4B (+21%).","Strategic productivity initiative expanded to deliver ~$2B additional cost savings by end of 2027.","2025 guidance: revenues ~$45.5B, Non-GAAP EPS range $6.55-$6.85."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":48300000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172638,"accession_number":"0001140361-25-000885","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb posts investor presentation at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on Jan 13, 2025, by CEO Christopher Boerner at the 43rd Annual J.P. Morgan Healthcare Conference.","Exhibit 99.1 contains only a title slide; no new financial data or guidance disclosed in the filing.","Filing under Item 7.01; information is furnished, not filed, per Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189648,"accession_number":"0000014272-24-000145","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q3 2024 revenue $11.9B (+8% YoY); raises full-year guidance, Cobenfy approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenues $11.9B, up 8% (+10% ex-FX); GAAP EPS $0.60, Non-GAAP EPS $1.80.","Growth Portfolio revenues $5.8B, up 18% (+20% ex-FX).","U.S. approval of Cobenfy (schizophrenia) achieved in Q3.","Raising 2024 revenue guidance to ~+5% (+6% ex-FX); Non-GAAP EPS range raised to $0.75–$0.95.","Net impact of acquired IPRD charges and licensing income reduced EPS by $0.09 on both GAAP and Non-GAAP."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":35958000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206137,"accession_number":"0000014272-24-000121","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol Myers Q2 rev $12.2B (+9%), non-GAAP EPS $2.07, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $12.2B up 9% YoY (+11% ex-FX); Growth Portfolio $5.6B up 18% (+21% ex-FX).","GAAP EPS $0.83, non-GAAP EPS $2.07; includes $(0.04) per share net impact from IPRD and licensing.","Raising 2024 non-GAAP guidance; U.S. approvals of Breyanzi for follicular and mantle cell lymphoma.","Subcutaneous nivolumab under regulatory review in U.S. and E.U.","CEO Boerner cited progress on commercial execution and pipeline advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":24066000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223186,"accession_number":"0001140361-24-030533","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bristol Myers Squibb elects former Agilent CEO Michael McMullen to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael R. McMullen elected to board, effective July 1, 2024; board size increases to 11.","McMullen served as Agilent CEO 2015-2024, nearly tripled market cap; independent director.","He will serve on Audit Committee; receives $110k annual retainer + $210k in deferred share units."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223185,"accession_number":"0001140361-24-025213","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Bristol-Myers Squibb shareholders approve charter amendment limiting executive officer liability, elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to eliminate/limit monetary liability for breach of duty of care for specified executive officers approved by majority of outstanding shares.","All 10 director nominees elected; votes ranged from 1.38B to 1.48B 'for' with minimal 'against'.","Advisory vote on named executive officer compensation passed (1.40B for, 82.96M against).","Deloitte & Touche ratified as independent auditor for 2024 (1.71B for, 45.39M against).","Two shareholder proposals (independent board chair, executive stock retention) did not pass."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223184,"accession_number":"0000014272-24-000094","cik":14272,"company_name":"BRISTOL MYERS SQUIBB CO","ticker":"BMY","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bristol-Myers Squibb Q1 revenue up 5% to $11.9B; GAAP loss per share $5.89 on acquired IPRD charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenues $11,865M (+5% reported, +6% ex-FX); growth portfolio revenues $4,767M (+8%, +11% ex-FX).","GAAP loss per share ($5.89); Non-GAAP loss per share ($4.40); includes $6.30/share impact from acquired IPRD and licensing.","Completed acquisitions of Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune collaboration.","Announced strategic productivity initiative targeting ~$1.5B in cost savings, majority reinvested for innovation.","Updated 2024 non-GAAP EPS and line-item guidance to reflect recent transactions; Abecma and Breyanzi received new U.S. approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":11865000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117459938076.48181,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}